Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Platform collecting

Oxford Genome Sciences Ltd. has done two deals in the last few months that should enable it to realize management's vision of transitioning from a biomarker services business into a therapeutics company by leveraging targets from its proteomics database. Last week's deal to develop cancer antibodies with Amgen Inc. gives the U.K. company access to its second antibody platform.

Oxford Genome (Abingdon, U.K.) was founded in 2003 when CEO

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers